Pharmaceutical Business review

Akorn-Strides wins FDA approval for pamidronate disodium injection

Pamidronate disodium injection is indicated for the treatment of hypercalcemia associated with malignancy and Paget’s disease.

Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said: “We are pleased to announce the abbreviated new drug application approval for pamidronate disodium injection.”